Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-08-15 DOI:10.1111/irv.13360

Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Reinout Naesens, Maria-Louise Borg, Goranka Petrović, Terra Fatukasi, Ligita Jancoriene, Ausenda Machado, Beatrix Oroszi, Petr Husa, Mihaela Lazar, Ralf Dürrwald, Jennifer Howard, Aryse Melo, Gloria Pérez-Gimeno, Jesús Castilla, Eva Bernaert, Aušra Džiugytė, Zvjezdana Lovrić Makarić, Margaret Fitzgerald, Auksė Mickienė, Verónica Gomez, Gergő Túri, Lenka Součková, Alexandru Marin, Kristin Tolksdorf, Nathalie Nicolay, Angela M. C. Rose, the European Hospital Vaccine Effectiveness Group

{"title":"Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024","authors":"Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Reinout Naesens, Maria-Louise Borg, Goranka Petrović, Terra Fatukasi, Ligita Jancoriene, Ausenda Machado, Beatrix Oroszi, Petr Husa, Mihaela Lazar, Ralf Dürrwald, Jennifer Howard, Aryse Melo, Gloria Pérez-Gimeno, Jesús Castilla, Eva Bernaert, Aušra Džiugytė, Zvjezdana Lovrić Makarić, Margaret Fitzgerald, Auksė Mickienė, Verónica Gomez, Gergő Túri, Lenka Součková, Alexandru Marin, Kristin Tolksdorf, Nathalie Nicolay, Angela M. C. Rose, the European Hospital Vaccine Effectiveness Group","doi":"10.1111/irv.13360","DOIUrl":null,"url":null,"abstract":"<p>We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13360","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13360","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Abstract Image

查看原文本刊更多论文

早期 COVID-19 XBB.1.5 疫苗对接种目标成人住院治疗的有效性，欧洲 VEBIS 医院网络，2023 年 10 月至 2024 年 1 月。

我们在 2023 年 10 月至 2024 年 1 月期间对欧洲因严重急性呼吸道感染住院的年龄≥ 18 岁的成年患者进行了一项多中心阴性病例对照研究。我们提供了新改良的 XBB.1.5 COVID-19 疫苗对 PCR 证实的 SARS-CoV-2 住院患者的有效性的早期估计。疫苗的总体有效率为 49%，接种后 14-29 天的有效率为 69%，接种后 60-105 天的有效率为 40%。经改良的 XBB.1.5 COVID-19 疫苗可在接种后的前 3.5 个月内预防 COVID-19 住院治疗，老年人（≥ 65 岁）在接种后 1 个月内的 VE > 70%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.